[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure].
作者信息
Kow C S, Ramachandram D S, Hasan S S
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malasia.
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, Malasia.
出版信息
Rev Clin Esp. 2022 May;222(5):309-310. doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.
Abstract
摘要
相似文献
1
[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure].[新型冠状病毒肺炎合并心力衰竭患者的糖皮质激素治疗]
Rev Clin Esp. 2022 May;222(5):309-310. doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.
2
Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure.新冠病毒病合并心力衰竭患者的糖皮质激素治疗
Rev Clin Esp (Barc). 2022 May;222(5):309-310. doi: 10.1016/j.rceng.2021.11.002. Epub 2022 Jan 31.
3
Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence.对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复。
Rev Clin Esp (Barc). 2022 May;222(5):310-311. doi: 10.1016/j.rceng.2021.11.001. Epub 2022 Jan 24.
4
[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence].[对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复]
Rev Clin Esp. 2022 May;222(5):310-311. doi: 10.1016/j.rce.2021.11.001. Epub 2021 Nov 20.
5
Association between glucocorticoid use and all-cause mortality in critically ill patients with heart failure: A cohort study based on the MIMIC-III database.糖皮质激素使用与重症心力衰竭患者全因死亡率之间的关联：一项基于MIMIC-III数据库的队列研究。
Front Pharmacol. 2023 Jan 12;14:1118551. doi: 10.3389/fphar.2023.1118551. eCollection 2023.
6
[Clinical effect of Shenfu injection combined with glucocorticoid on patients with acute left heart failure complicated with bronchospasm].参附注射液联合糖皮质激素治疗急性左心衰竭合并支气管痉挛患者的临床疗效
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Dec;35(12):1298-1303. doi: 10.3760/cma.j.cn121430-20230726-00557.
7
Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.糖皮质激素治疗 COVID-19 肺炎患者的临床疗效：一项单中心经验。
Biomed Pharmacother. 2020 Oct;130:110529. doi: 10.1016/j.biopha.2020.110529. Epub 2020 Jul 28.
8
Glucocorticoid pulse therapy in an elderly patient with post-COVID-19 organizing pneumonia: A case report.糖皮质激素脉冲疗法治疗老年新型冠状病毒肺炎后机化性肺炎1例报告
World J Clin Cases. 2023 Jun 16;11(17):4152-4158. doi: 10.12998/wjcc.v11.i17.4152.
9
Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure: COPE-ADHF study.糖皮质激素对急性失代偿性心力衰竭的心脏结局预防效果：COPE-ADHF研究
J Cardiovasc Pharmacol. 2014 Apr;63(4):333-8. doi: 10.1097/FJC.0000000000000048.
10
General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19.关于新型冠状病毒肺炎（COVID-19）患者糖皮质激素诱导性骨坏死风险评估与管理的一般建议。
J Orthop Translat. 2021 Nov;31:1-9. doi: 10.1016/j.jot.2021.09.005. Epub 2021 Oct 20.
引用本文的文献
1
Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence.对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复。
Rev Clin Esp (Barc). 2022 May;222(5):310-311. doi: 10.1016/j.rceng.2021.11.001. Epub 2022 Jan 24.
2
[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence].[对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复]
Rev Clin Esp. 2022 May;222(5):310-311. doi: 10.1016/j.rce.2021.11.001. Epub 2021 Nov 20.
本文引用的文献
1
Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study.因COVID-19住院的心力衰竭患者的皮质类固醇治疗：一项多中心回顾性研究。
Intern Emerg Med. 2021 Nov;16(8):2301-2305. doi: 10.1007/s11739-021-02843-4. Epub 2021 Oct 12.
2
IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?白细胞介素-6拮抗剂能否取代全身用皮质类固醇，成为新冠病毒病患者首选的抗炎治疗药物？
Cytokine. 2022 Jan;149:155730. doi: 10.1016/j.cyto.2021.155730. Epub 2021 Oct 5.
3
Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.COVID-19 相关死亡风险因素：42 项研究和 423117 例患者的系统评价和荟萃分析。
BMC Infect Dis. 2021 Aug 21;21(1):855. doi: 10.1186/s12879-021-06536-3.
4
[Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain].[西班牙因COVID-19住院的心力衰竭患者入院时的临床特征及死亡风险因素]
Rev Clin Esp. 2022 May;222(5):255-265. doi: 10.1016/j.rce.2021.06.004. Epub 2021 Jul 17.
5
Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.甲泼尼龙是否降低住院 COVID-19 患者的死亡风险？一项随机对照试验的荟萃分析。
Expert Rev Respir Med. 2021 Aug;15(8):1049-1055. doi: 10.1080/17476348.2021.1925546. Epub 2021 Jul 2.
6
The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.COVID-19 患者进展和死亡的常见危险因素：荟萃分析。
Arch Virol. 2021 Aug;166(8):2071-2087. doi: 10.1007/s00705-021-05012-2. Epub 2021 Apr 2.
7
Dexamethasone or hydrocortisone in COVID-19?新冠肺炎中使用地塞米松还是氢化可的松？
Cleve Clin J Med. 2020 Nov 23;87(12):715. doi: 10.3949/ccjm.87c.12005.
8
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
9
Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance.糖皮质激素对利尿剂抵抗的心力衰竭患者利尿作用的增强效果。
J Card Fail. 2014 Sep;20(9):625-9. doi: 10.1016/j.cardfail.2014.06.353. Epub 2014 Jun 23.
10
Basic and clinical pharmacology of glucocorticosteroids.糖皮质激素的基础与临床药理学
Anesth Prog. 2013 Spring;60(1):25-31; quiz 32. doi: 10.2344/0003-3006-60.1.25.
Zotero 插件